Retatrutide vs Wegovy: Weight Loss Comparison, Side Effects & Differences

Overview

Retatrutide and Wegovy treat obesity in two different ways. Wegovy (semaglutide 2.4 mg, Novo Nordisk) is an FDA-approved weekly GLP-1 receptor agonist injection, indicated for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Retatrutide (LY3437943, Eli Lilly) is an investigational triple agonist that targets the GIP, GLP-1 and glucagon receptors at once. It is in Phase 3 clinical development.

People look up this comparison more than almost any other in obesity medicine, for good reason. Wegovy is the current benchmark for obesity drugs, and retatrutide’s TRIUMPH-4 Phase 3 data (-28.7% mean weight loss at 68 weeks) suggest it may beat that benchmark by a wide margin. Below we cover how they differ in mechanism, efficacy, safety and availability.

Important note: No clinical trial has compared retatrutide with Wegovy directly. Every efficacy comparison here is cross-trial, with major limits from differences in study populations, trial design, length and how outcomes were measured. These comparisons are for context only and are not definitive evidence of which drug works better. The one head-to-head trial of retatrutide against semaglutide, TRANSCEND-T2D-2, used the 2 mg Ozempic dose in adults with type 2 diabetes, not Wegovy’s 2.4 mg obesity dose.

Mechanism of Action

Wegovy (Semaglutide 2.4 mg)

Wegovy contains semaglutide, a selective GLP-1 receptor agonist with 94% structural similarity to natural human GLP-1. It causes weight loss only through GLP-1 receptor pathways:

• Appetite suppression through GLP-1 receptors in the hypothalamus and brainstem, which reduces hunger and increases fullness
• Delayed gastric emptying, so you stay full longer after meals
• Glucose-dependent insulin secretion and glucagon suppression
• Possible heart-protective effects through GLP-1R signaling in blood vessels

Wegovy’s 2.4 mg dose is higher than the 0.5 to 2 mg doses in Ozempic (the diabetes brand) and is chosen specifically for weight management. The molecule is identical in both products; only the dose and approved use differ. A C18 fatty diacid extends its half-life to about 7 days, allowing weekly dosing.

Retatrutide

Retatrutide engages three separate receptor pathways at once. Beyond the GLP-1 receptor effects it shares with Wegovy, it activates:

• GIP receptors, which remodel fat tissue, boost insulin secretion and may add to appetite control in the brain. GIP receptor activation may also affect gut motility in a way that partly offsets GLP-1-driven nausea.
• Glucagon receptors, which raise energy use in the liver, promote fat burning and stimulate heat production. This is the key difference: the glucagon component makes the body burn more calories rather than only eat fewer.

That gives retatrutide a very different profile. Wegovy cuts energy intake by suppressing appetite. Retatrutide cuts intake (via GLP-1R and GIPR) and raises energy use (via GCGR), producing a larger energy deficit.

Why the Mechanism Difference Matters Clinically

The difference shows up at the weight loss plateau. With Wegovy, weight loss usually levels off around 60-68 weeks, as the body’s metabolic adaptation (a lower resting metabolic rate) balances out the appetite suppression. Retatrutide’s glucagon component pushes back against that adaptation by keeping energy use high. That may explain why retatrutide’s Phase 2 weight loss curve had not flattened at 48 weeks, and why the Phase 3 TRIUMPH-4 results beat Phase 2 instead of falling short.

Retatrutide is a 39-amino-acid synthetic peptide with a molecular weight of about 4,731 Da. Like Wegovy, it uses a fatty acid chain (C20) to bind albumin and extend its half-life (~6 days), allowing a weekly injection under the skin.

Efficacy Comparison

Weight Loss

Clinical trial data show a large numerical gap between the two drugs:

Parameter	Wegovy (Semaglutide 2.4 mg)	Retatrutide 12 mg (Phase 2)	Retatrutide (TRIUMPH-4, Phase 3)
Trial	STEP 1 (Phase 3)	Phase 2 obesity	TRIUMPH-4 (Phase 3)
Duration	68 weeks	48 weeks	68 weeks
Population	BMI ≥30 or ≥27 with comorbidity	Obesity/overweight	Obesity with knee OA
Mean weight loss	-14.9%	-24.2%	-28.7%
≥5% weight loss	~86%	~100%	Not in topline release
≥10% weight loss	~70%	~93%	Not in topline release
≥15% weight loss	~50%	~83%	Not in topline release
≥20% weight loss	~32%	~73%	Not in topline release
≥25% weight loss	—	—	58.6%
≥30% weight loss	—	—	39.4%

The TRIUMPH-4 Phase 3 result of -28.7% mean weight loss at 68 weeks is the standout number here. It is nearly double Wegovy’s -14.9% over the same treatment period (both 68 weeks). Put simply, an average participant weighing 100 kg at baseline would lose about 28.7 kg on retatrutide versus about 14.9 kg on Wegovy.

Significance of the Phase 3 Confirmation

The TRIUMPH-4 results count for more than Phase 2 data for one key reason: Phase 3 trials enroll larger, more varied populations under conditions closer to everyday practice. Phase 2 results routinely look better than Phase 3, because smaller samples, more selected patients and tighter protocol adherence all tilt toward stronger results. Retatrutide’s Phase 3 result (-28.7%) beating its Phase 2 result (-24.2%) is unusual, and it makes the drug’s profile more convincing.

Weight Loss Trajectory

In STEP 1, Wegovy’s weight loss seemed to near a plateau around 60 to 68 weeks. Retatrutide’s Phase 2 curve at 48 weeks was still falling, with participants still losing weight at the last check. The difference may come from glucagon-driven energy use, which could keep weight loss going beyond what appetite suppression alone can do.

If retatrutide’s weight loss keeps going past 48 weeks without flattening, as the curve suggests it might, the final total could reach or pass 30%, a level once reached only with bariatric surgery.

Liver Fat Reduction

This is one of the most clinically important differences:

Parameter	Wegovy	Retatrutide
Relative liver fat reduction	~40-50% (from semaglutide MASLD studies)	~82% (Phase 2)
Primary mechanism	Indirect: weight loss, insulin sensitivity	Direct: GCGR-mediated hepatic fatty acid oxidation + indirect
Clinical significance	FDA-approved for MASH with moderate-to-advanced fibrosis (accelerated approval, August 2025)	Potentially transformative for MASLD/MASH (not approved)

The roughly 30-40 percentage point gap in liver fat reduction is one of the clearest mechanistic differences between the two. Retatrutide’s glucagon component directly tells liver cells to burn stored fat, an effect Wegovy, with no glucagon activity, cannot reproduce at any dose.

Safety Comparison

Gastrointestinal Effects

The most common side effects of both drugs are the GI effects driven by GLP-1 receptor activation:

Adverse Event	Wegovy 2.4 mg (US label)	Retatrutide 12 mg (TRIUMPH-4, 68 weeks)
Nausea	44%	43.2%
Diarrhea	30%	33.1%
Vomiting	24%	20.9%
Constipation	24%	25.0%
Discontinuation due to AEs	6.8%	18.2%

In these figures, retatrutide’s GI rates are close to Wegovy’s (nausea 43.2% vs 44%, diarrhea 33.1% vs 30%, vomiting 20.9% vs 24%). Stopping treatment because of side effects was more common with retatrutide 12 mg in TRIUMPH-4; in the later TRIUMPH-1 trial it was 11.3% at 12 mg. These are cross-trial comparisons.

With both drugs, GI side effects are usually:

• Most pronounced during dose escalation (first 4-8 weeks)
• Mild to moderate in severity for the majority of patients
• Transient, improving with continued treatment
• Manageable through dietary modifications (smaller meals, avoiding high-fat foods)

Cardiovascular Considerations

Wegovy has a big advantage in cardiovascular evidence. The SELECT trial showed that semaglutide 2.4 mg cut major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease. That landmark result led to an expanded FDA indication for cardiovascular risk reduction and is one of the most important points in Wegovy’s favor.

Retatrutide has no cardiovascular outcomes data. Phase 2 showed improvements in risk factors (lower blood pressure, better lipids), but dedicated outcomes trials are needed to establish cardiovascular safety or benefit. Since heart disease is the leading cause of death in people with obesity, this gap matters.

Dysesthesia

TRIUMPH-4 Phase 3 data also found a new safety signal: dysesthesia (tingling, numbness or burning sensations), reported in 20.9% of the 12 mg group versus 0.7% on placebo. It was not prominent in Phase 2. It is thought to be linked to glucagon receptor activity and has not been seen at similar rates with semaglutide or other GLP-1-only drugs.

Heart Rate and Blood Pressure

Both raise heart rate. The Wegovy label reports mean increases in resting heart rate of 1 to 4 beats per minute compared with placebo. In retatrutide’s Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and then declined; the main paper does not give the size of the rise. Both lower blood pressure, probably through weight loss and possibly direct effects on blood vessels. Retatrutide’s glucagon component may add further circulatory effects, though current data do not show whether they matter clinically.

Gallbladder Events

Rapid weight loss from any cause raises the risk of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). This is not specific to the drug; it happens because cholesterol is released quickly as fat is broken down. Wegovy’s STEP trials reported gallbladder events in about 1.5-2.5% of patients. Retatrutide’s larger weight loss could in theory raise this risk, so watching for gallbladder events in Phase 3 will be important.

Pancreatitis

Both drugs carry warnings about possible pancreatitis, a class concern with incretin-based drugs. Rates are low (<1%) with semaglutide in large Phase 3 and real-world datasets. Retatrutide’s Phase 2 data showed no raised pancreatitis signal, but larger Phase 3 populations have more power to detect this rare event.

Thyroid Considerations

Wegovy carries a boxed warning about thyroid C-cell tumor risk based on rodent studies of GLP-1 receptor agonists. After years of monitoring, its relevance in people has still not been established. Retatrutide’s thyroid safety in people is being studied in the Phase 3 program.

Body Composition Considerations

With weight loss above 25%, body composition becomes a serious concern. Not all weight loss is equal. Losing fat improves metabolic health, while losing lean mass (muscle, bone) can weaken physical function, lower metabolic rate and raise frailty risk.

Wegovy

STEP trial data show that about 60-70% of the weight lost on Wegovy is fat and 30-40% is lean mass. That ratio is typical of weight loss from eating less and has been debated among clinicians. At 15% total weight loss, the amount of lean mass lost is moderate and usually well tolerated, especially in younger patients.

Retatrutide

Retatrutide’s body composition is still being studied in Phase 3. Two opposing effects are at work: glucagon receptor activation speeds amino acid breakdown (which may increase lean mass loss) but also strongly drives fat burning (which may shift the body toward using fat rather than protein for fuel). The net effect at -28.7% weight loss is an important open question.

At the amount of weight retatrutide removes, even a similar lean-to-fat ratio means much more lean mass lost in absolute terms. For a 100 kg patient losing 28.7 kg, about 9-11 kg could be lean mass, enough to need attention.

Practical Mitigation

For both drugs, clinical guidelines increasingly recommend:

• Adequate protein intake (≥1.2-1.6 g/kg/day of ideal body weight)
• Resistance exercise at least 2-3 times per week
• Monitoring of functional capacity and muscle strength during treatment
• Bone density assessment in at-risk populations

Dose Titration and Practical Use

Wegovy Dosing

Wegovy uses a well-established 16-20 week dose-escalation schedule: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg and 1.7 mg for 4 weeks each, then the maintenance dose of 2.4 mg. A higher 7.2 mg dose, sold as Wegovy HD, was approved in the US in March 2026 and launched in April. The gradual increase greatly reduces GI side effects at the start. The schedule has been refined through wide clinical experience and prescribers know it well.

Wegovy comes in a prefilled pen that you use yourself at home. The injection site (abdomen, thigh, upper arm) is rotated each week. The FDA declared the US semaglutide shortage resolved on February 21, 2025.

Retatrutide Dosing

In clinical trials, retatrutide’s dose escalation aims for a 12 mg maintenance dose. The titration schedule refined for Phase 3 likely helped TRIUMPH-4’s results improve on Phase 2. Once the drug is approved, the prescribing information will set the titration schedule for clinical use.

Both drugs are once-weekly injections under the skin, so the practical burden is about the same.

Patient Population-Specific Considerations

Severe Obesity (BMI ≥40)

For people with severe obesity, the gap between Wegovy (-14.9%) and retatrutide (-28.7%) matters most. Someone starting at 140 kg would lose about 21 kg on Wegovy versus about 40 kg on retatrutide. The second figure approaches what bariatric surgery achieves and could mean the difference between modest improvement and life-changing results: sleep apnea resolved, diabetes in remission, mobility restored and less need for joint replacement.

MASLD/MASH

The liver fat data strongly favor retatrutide for people with metabolic dysfunction-associated steatotic liver disease. A ~82% relative liver fat reduction versus ~40-50% could mean the difference between partial improvement and fatty liver almost fully cleared. MASLD affects about 25-30% of adults worldwide and is the fastest-growing cause of liver transplants, so this difference matters for public health.

Cardiovascular Disease

Wegovy has a proven cardiovascular advantage from the SELECT trial (20% MACE reduction). For people with established cardiovascular disease or high cardiovascular risk, Wegovy is the evidence-based choice until retatrutide produces comparable outcomes data.

Post-Bariatric Surgery

A growing question is whether drugs can add to the results of bariatric surgery. Some people regain weight after surgery, and Wegovy has helped in this group. Retatrutide has not been studied after surgery, but its larger weight loss makes it a candidate for future study here.

Key Differences Summary

Feature	Wegovy	Retatrutide
Receptor targets	GLP-1 only	GIP + GLP-1 + Glucagon
Molecular weight	~4,114 Da	~4,731 Da
Approval status	FDA-approved (2021)	Investigational (Phase 3)
Indication	Chronic weight management, CV risk, MASH with moderate-to-advanced fibrosis	Not yet approved
Manufacturer	Novo Nordisk	Eli Lilly
Administration	Once-weekly SC injection	Once-weekly SC injection
Weight loss (Phase 3, cross-trial)	-14.9% at 68 weeks	-28.7% at 68 weeks
Liver fat reduction	~40-50%	~82%
CV outcomes data	Yes (SELECT trial)	No
Real-world experience	Extensive (millions of patients)	None
Mechanism of weight loss	Appetite suppression	Appetite suppression + increased energy expenditure
Expected cost	$1,349/month list price (February 2026); $675 planned from January 2027	Unknown

Status and Availability

Parameter	Wegovy	Retatrutide
FDA approval	Approved June 2021	Not approved
Current phase	Post-marketing	Phase 3 (TRIUMPH program)
Phase 3 weight loss confirmed	Yes	Yes (TRIUMPH-4: -28.7%)
Cardiovascular indication	Yes (SELECT, 2024)	Not studied
Prescribable	Yes	No (clinical trials only)
Expected availability	Now	Late 2027 to mid-2028 (filing planned no later than Q1 2027)
Supply situation	US shortage declared resolved February 2025	Not applicable
Oral formulation	Yes: Wegovy pill (oral semaglutide 25 mg, approved December 2025)	Not in development
Insurance coverage	Variable, expanding	Not applicable

In practice it is simple. Wegovy is available now, with established prescribing, insurance coverage (where it applies) and years of real-world experience behind it. Retatrutide is 1-2 years from the earliest possible approval, with Lilly planning to file no later than Q1 2027. If you are deciding on treatment today, consider Wegovy and other approved options rather than waiting for retatrutide.

Cost, Insurance, and Access

Wegovy

Wegovy’s list price was $1,349 per month as of February 2026; Novo Nordisk says it will cut it to $675 from January 1, 2027. Self-pay prices are lower: $349 a month for most injectable doses (February 2026) and $149 to $299 a month for the Wegovy pill, depending on dose (August 2026). Insurance coverage has grown since approval but is still patchy. Since July 1, 2026, Medicare Part D enrollees who meet CMS clinical criteria can get Wegovy for $50 a month through the temporary Medicare GLP-1 Bridge, which runs through December 31, 2027. Many private insurers still limit coverage or require prior authorization. Patient assistance programs and manufacturer savings cards fill some of the gap. Cost has a big effect on whether people can start and stay on treatment.

Retatrutide

Retatrutide’s price is unknown, but several factors will shape it:

• If Eli Lilly prices it above tirzepatide (to reflect greater efficacy), the monthly cost could exceed $1,500
• Greater weight loss may improve cost-effectiveness if it produces proportionally better clinical outcomes
• Insurance coverage will depend on the approved indications and the strength of the clinical evidence package
• Competition with CagriSema and next-generation GLP-1 agonists could moderate pricing

The economics of obesity treatment are changing. As evidence builds that drug-based weight loss cuts long-term healthcare costs (fewer heart attacks and strokes, diabetes complications, joint replacements and cancer diagnoses), payers are slowly becoming less resistant to covering it.

Long-Term Durability and Weight Regain

A key question for both drugs is how long the weight loss lasts and what happens when treatment stops.

Wegovy: The STEP 1 extension and the STEP 4 withdrawal study showed significant regain after semaglutide was stopped: patients regained about two-thirds of the lost weight within one year. So Wegovy has to be taken long term to keep its benefit. It is not a “course of treatment” you finish; it is ongoing therapy, like blood pressure medication.

Retatrutide: There are no data on stopping. Its glucagon component raises an interesting question: if GCGR-driven changes in liver metabolism or energy use cause lasting metabolic changes, some benefit might persist after stopping. That is pure speculation. The safest assumption is that retatrutide, like all incretin drugs, will need to be taken long term.

For this comparison, that means long-term cost, tolerability and safety matter even more than short-term efficacy. A drug that produces 28.7% weight loss but must be taken indefinitely raises different questions than one used for a fixed period.

Clinical Implications

Wegovy is still the standard of care for drug treatment of obesity, backed by solid Phase 3 data, wide real-world experience and cardiovascular outcomes evidence. Its established safety profile, availability and insurance coverage (where it applies) make it a well-understood choice.

TRIUMPH-4’s Phase 3 data have moved retatrutide from a promising Phase 2 candidate to a Phase 3-validated drug with the strongest weight loss ever shown for a single obesity medicine. Its -28.7% mean weight loss far exceeds Wegovy’s benchmark and approaches what bariatric surgery has historically achieved.

But efficacy is only one part of a drug’s profile. Retatrutide still has to show:

• Consistent safety across the full Phase 3 program
• Long-term durability of weight loss beyond 68 weeks
• Acceptable body composition changes (lean mass preservation)
• Manageable side effect profile in diverse populations
• Cardiovascular safety (and ideally, benefit)

For clinicians and patients deciding now, Wegovy is an available, proven option. Retatrutide may be the biggest advance in obesity drugs in a decade, but it will not reach clinical practice until late 2027 at the earliest. Whether to wait or start treatment now should depend on how urgent your situation is, your other conditions and your goals.

Summary of Key Comparisons

Metric	Wegovy	Retatrutide (TRIUMPH-4)
Phase 3 weight loss	-14.9% (68 weeks)	-28.7% (68 weeks)
Weight loss at plateau?	Yes (~60-68 weeks)	Not yet at 68 weeks
Liver fat reduction	~40-50%	~82%
CV outcomes benefit	Yes (20% MACE reduction)	Not studied
Nausea rate (Wegovy label; retatrutide 12 mg)	44%	43.2%
Vomiting rate	24%	20.9%
Receptors targeted	GLP-1 only	GIP + GLP-1 + Glucagon
Approval status	FDA-approved (2021)	Phase 3
Oral option	Yes (Wegovy pill, 25 mg)	No
Earliest availability	Now	Late 2027 to mid-2028

Frequently Asked Questions

Is retatrutide better than Wegovy for weight loss?

Phase 3 data strongly suggest retatrutide produces more weight loss. TRIUMPH-4 showed -28.7% mean weight loss at 68 weeks, compared with Wegovy’s -14.9% at 68 weeks in STEP 1. The nearly twofold difference comes from retatrutide’s extra receptor targets, especially the glucagon receptor, which raises energy use. But these are cross-trial comparisons, there is no head-to-head study, and “better” means more than efficacy. Safety, availability, cardiovascular outcomes and cost all matter.

When will retatrutide be available as an alternative to Wegovy?

Retatrutide is in Phase 3 clinical trials and has not been submitted for approval. The earliest realistic FDA approval is late 2027 to mid-2028, with Lilly planning to file no later than Q1 2027. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA), which Lilly is contesting (the FDA ruling). If you are considering obesity treatment now, do not put off an approved drug like Wegovy while waiting for retatrutide. If retatrutide is approved, you could possibly switch to it under medical supervision.

Does retatrutide have fewer side effects than Wegovy?

Phase 3 TRIUMPH-4 data showed retatrutide 12 mg has GI rates over 68 weeks similar to Wegovy (nausea 43.2% vs 44%, diarrhea 33.1% vs 30%, vomiting 20.9% vs 24% in the Wegovy label). The key safety point is that Wegovy has years of real-world data behind its safety profile, while retatrutide’s long-term safety is still being worked out.

Can I switch from Wegovy to retatrutide?

Not yet. Retatrutide is investigational and not available by prescription. If it is approved, switching from Wegovy would be a decision for you and your doctor. The drugs act on overlapping but different receptors: retatrutide activates GIP and glucagon receptors on top of the GLP-1 pathway Wegovy targets. A dose titration period would probably be needed. There are no clinical data on switching yet.

Which drug is better for fatty liver: retatrutide or Wegovy?

Retatrutide appears to have a clear advantage. Phase 2 data showed about an 82% relative drop in liver fat with retatrutide, compared with roughly 40-50% with semaglutide (the active ingredient in Wegovy) in MASLD studies. The difference is put down to retatrutide’s glucagon receptor activity, which directly stimulates fat burning in liver cells. For people with metabolic dysfunction-associated steatotic liver disease (MASLD), this could be the most important clinical difference between the two drugs.

Does Wegovy have any advantages over retatrutide?

Yes, several. Wegovy is FDA-approved and available now. It has proven cardiovascular benefit from the SELECT trial (20% reduction in major cardiovascular events). It has years of real-world safety data from millions of patients. A pill version for weight management, the Wegovy pill (oral semaglutide 25 mg), was approved in December 2025. Insurance coverage is established. And its single-receptor mechanism is well understood. Retatrutide may prove the stronger weight loss drug, but Wegovy’s maturity, accessibility and cardiovascular evidence are real advantages that will still count after retatrutide reaches the market.